Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

541.68 +60.21 (+12.51%)
Streaming Delayed Price Updated: 12:35 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions ↗
United Therapeutics (NASDAQ:UTHR) outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors... 
Via MarketBeat
News headline image
Why United Therapeutics (UTHR) Shares Are Falling Today
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 4% in the afternoon session after Goldman Sachs initiated coverage of t... 
Via StockStory
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock ↗
Via Chartmill
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Tumbles as Q2 Revenue Misses Despite EPS Beat ↗
Via Chartmill
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Ove... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Profitable Stocks We’re Skeptical Of
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗
CEO Rothblatt calls H1 2026 "one of the most consequential periods" in company history. 
Via The Motley Fool
Topics Earnings
News headline image
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting ... 
Via StockStory
Topics Earnings
News headline image
UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
Biotechnology company United Therapeutics (NASDAQ:UTHR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 m... 
Via StockStory
News headline image
United Therapeutics Q2 Earnings Call Highlights ↗
United Therapeutics (NASDAQ:UTHR) reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized... 
Via MarketBeat
Topics Earnings
News headline image
United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 1.9% year on yea... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before the bell. Here’s what you need to know. United Therap... 
Via StockStory
News headline image
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors? ↗
Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while maintaining $353.1 million in equity value. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Acquires Thymmune Therapeutics
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.